Therapeutic Advances in Heart failure

Costs of providing a particular medical service can be measured, but it is more difficult to assess whether the service provides good value for the money spent. Extensive cost-effectiveness studies have been conducted on many important cardiovascular therapies:

  • β-blockers and diuretics for multiple CVD outcomes, mortality, and prevention of recurrent myocardial infarction (MI);
  • Statins for both primary and secondary prevention of CVD;
  • Enalapril for prevention and treatment of congestive heart failure;
  • Tissue plasminogen activator treatment of acute MI;
  • Coronary artery bypass graft for left main, single-, and 2-vessel coronary artery disease, or severe angina;
  • Physician counselling for smoking; and
  • Radiofrequency ablation therapy for Wolff-Parkinson-White syndrome.
  • Anticoagulation Therapy and Thrombosis Prevention
  • Aortic Stenosis and TAVR